BioMed Research International

BioMed Research International / 2021 / Article
Special Issue

Applications of Bioinformatics and Systems Biology in Precision Medicine and Immuno-Oncology 2021

View this Special Issue

Research Article | Open Access

Volume 2021 |Article ID 5587441 |

Dazhong Liu, Pengfei Zhang, Jiaying Zhao, Lei Yang, Wei Wang, "Identification of Molecular Characteristics and New Prognostic Targets for Thymoma by Multiomics Analysis", BioMed Research International, vol. 2021, Article ID 5587441, 15 pages, 2021.

Identification of Molecular Characteristics and New Prognostic Targets for Thymoma by Multiomics Analysis

Academic Editor: Tao Huang
Received16 Jan 2021
Revised16 Mar 2021
Accepted01 Apr 2021
Published20 May 2021


Background. Thymoma is a heterogeneous tumor originated from thymic epithelial cells. The molecular mechanism of thymoma remains unclear. Methods. The expression profile, methylation, and mutation data of thymoma were obtained from TCGA database. The coexpression network was constructed using the variance of gene expression through WGCNA. Enrichment analysis using clusterProfiler R package and overall survival (OS) analysis by Kaplan-Meier method were carried out for the intersection of differential expression genes (DEGs) screened by limma R package and important module genes. PPI network was constructed based on STRING database for genes with significant impact on survival. The impact of key genes on the prognosis of thymoma was evaluated by ROC curve and Cox regression model. Finally, the immune cell infiltration, methylation modification, and gene mutation were calculated. Results. We obtained eleven coexpression modules, and three of them were higher positively correlated with thymoma. DEGs in these three modules mainly involved in MAPK cascade and PPAR pathway. LIPE, MYH6, ACTG2, KLF4, SULT4A1, and TF were identified as key genes through the PPI network. AUC values of LIPE were the highest. Cox regression analysis showed that low expression of LIPE was a prognostic risk factor for thymoma. In addition, there was a high correlation between LIPE and T cells. Importantly, the expression of LIPE was modified by methylation. Among all the mutated genes, GTF2I had the highest mutation frequency. Conclusion. These results suggested that the molecular mechanism of thymoma may be related to immune inflammation. LIPE may be the key genes affecting prognosis of thymoma. Our findings will help to elucidate the pathogenesis and therapeutic targets of thymoma.

1. Introduction

Thymoma is the most common anterior mediastinal compartment tumor, originating from the thymic epithelial cell population [1]. The incidence of thymomas is approximately 2.5 cases per million people per year, with an age distribution ranging from 10 to 80 years [2]. In addition, thymoma is often associated with autoimmune diseases, especially myasthenia gravis (MG) [3, 4]. However, the potential molecular oncogenesis of thymoma remains unknown. Generally, when a thymoma is diagnosed, the patient will receive surgical treatment. For stages III and IV patients, the 5-year survival rates were 74% and <25%, respectively [5]. At present, neither surgeon nor physician can predict the prognosis and metastasis status of thymoma patients through X-ray examination, nor can detailed treatment plan be formulated before operation [6]. Obviously, the establishment of additional predictors is very beneficial for the identification and treatment of thymoma.

The pathogenesis of thymoma is various, and the rapid development of “genome” technology, including whole-genome expression analysis and next-generation sequencing (NGS), provides new means to explore the complexity and map of genomic alterations in thymoma [79]. Epigenetic modifications, including epigenetic alterations, are a feature of cancer because they play an important role in the process of carcinogenesis [10, 11]. In addition, the thymus provides a special microenvironment for the development and selection of mature T cells. Recent evidence suggests that immune responses such as T cells are involved in the development of thymoma [12, 13]. However, the understanding of the pathogenesis of thymoma is still limited.

In recent years, with the development of molecular biology, more and more research projects have begun to explore methods to accurately predict the prognosis of thymoma. In this study, we used multiomics datasets from the tumor genome map (TCGA). The results may be helpful to understand the pathogenesis of thymoma and identify LIPE as a potential new therapeutic target through bioinformatics analysis. The novelty of this work is that we combined the variance and difference of gene expression to screen the genes related to the prognosis of thymoma through coexpression network and PPI network. Then, the key genes were further screened by methylation modification.

2. Materials and Methods

2.1. TCGA Dataset Processing and Coexpression Analysis

Thymoma mRNA-seq expression data, methylation data, mutation data, and clinical materials were obtained from TCGA website ( The variance of gene expression was calculated, and the top 1/4 genes were intercepted for coexpression analysis through weighted gene coexpression network analysis (WGCNA).

2.2. Screening of Differentially Expressed Genes

The differentially expressed genes (DEGs) between thymoma and control were identified by limma R package. Set the filtering threshold .

2.3. Construction of PPI Network

The gene was mapped into the STRING database ( to obtain the protein-protein interaction (PPI) network. A significant PPI network was obtained by comprehensive , which was demonstrated by the Cytoscape software. The selection of key genes was based on their association with other proteins: genes with higher connectivity were considered to play an important role in the PPI network [14, 15].

2.4. Enrichment Analysis

In order to analyze the biological functions and signaling pathways of differentially expressed genes in thymoma-related modules, we performed enrichment analysis. Gene Ontology (GO) and the Kyoto Encyclopaedia of Genes and Genomes (KEGG) were enriched by clusterProfiler R package. was the threshold used for the significant terms. Gene set enrichment analysis (GSEA) was performed with the GSEA software for genes [16, 17].

2.5. Differential Methylation and Mutation Analysis

The quality of the original probe data obtained from the methylated microarray was checked, including background correction, probe type difference adjustment, and probe exclusion. According to these in sample standardized procedures, DNA methylation was scored as a value. We used samr R package for differential methylation analysis. For a CpG site to be considered differentially methylated, the difference in the median value in thymoma and normal samples should be at least 0.1 and the value <0.05. The nonsilent mutation (gene-level) data were analyzed using Maftools R-package.

2.6. Statistical Analysis

Statistical analysis was performed using the SPSS software, version 23.0 (SPSS Inc., Chicago, USA). Kaplan-Meier method was used to estimate the overall survival (OS). Cox regression model and Cox proportional hazards regression method were used to identify predictors of OS [18]. value <0.05 was considered statistically significant [19].

3. Results

3.1. Coexpression of Genes in Thymoma

According to the variance results of thymoma gene expression, the top 1/4 genes with larger variance were selected for coexpression analysis. A coexpression network consisting of 5758 genes was obtained. Taken 0.9 as the threshold of correlation coefficient, select the soft threshold as 7 (Figure 1(a)). A total of 11 coexpression modules were identified through WGCNA analysis (Figure 1(b)). In addition, we calculated the correlation between module genes and thymoma. We found that MEgreen, MEblue, and MEturquoise had the highest correlation with tumor samples (Figure 1(c)). Furthermore, 2559 differentially expressed genes (DEGs) were screened between thymoma and control group () (Figure 1(d)).

3.2. Enrichment of Differentially Expressed Genes in Modules

Further, 913 intersection genes between DEGs and the three modules with the highest correlation were selected as the important genes for subsequent study and enrichment analysis. The results of GO enrichment showed that these genes were involved in 1234 biological processes (BP), 151 cell components (CC), and 214 molecular functions (MF). It mainly included cell growth, positive regulation of MAPK cascade, ERK1 and ERK2 cascade, response to transforming growth factor beta, and Wnt signaling pathway (Figure 2(a)). KEGG enrichment results showed a total of 40 terms, mainly involving cell adhesion molecules, ECM-receptor interaction, focal adhesion, and PPAR signaling pathway (Figure 2(b)). In addition, the GSEA results showed some of the same results as KEGG, mainly including cGMP-PKG signaling pathway, cholesterol metadata, and PPAR signaling pathway (Figure 2(c)). These same signaling pathways cover a large number of differentially expressed genes (Figure 2(d)).

3.3. Identification of Key Prognostic Genes

The overall survival (OS) analysis of selected important genes identified 88 genes with significant impact on prognosis (). Mapping these genes into the STRING database yielded a PPI network of 45 genes, which was displayed by Cytoscape (Figure 3(a)). The top six genes with the highest connectivity were analyzed in depth as key genes. Among them, the expression of MYH6 and SULT4A1 in osteosarcoma was higher than that in control group, while the expression of LIPE, ACTG2, KLF4, and TF was decreased (Figure 3(b)). In addition, high expression of LIPE and MYH6 could improve the OS of patients, and ACTG2, KLF4, SULT4A1, and TF decreased the OS of patients (Figure 3(c)). ROC curves showed that the AUC values of these six genes were all greater than 0.6, especially those of LIPE, and KLF4 and TF were greater than 0.9 (Figure 3(d)).

3.4. The Effect of Key Genes on Prognosis

Multivariate survival analysis was performed by Cox regression model, and nomogram was generated by Cox regression coefficients. The nomogram showed that low expression of LIPE was a risk factor for predicting the overall survival time of thymoma at 5 and 8 years (Figure 4(a)). Calibration plots showed that the nomograms performed well compared with an ideal model (Figure 4(b)). In addition, Cox risk ratio model suggested that the survival rate of the high-risk population for thymoma was poor (Figure 4(c)). Among them, low expression of LIPE and MYH6 and high expression of ACTG2, KLF4, SULT4A1, and TF were important risk factors.

3.5. Changes of Immune Microenvironment in Thymoma

By comparing the immune cell infiltration between thymoma and control, we found that dendritic cells (DC) decreased most significantly in thymoma (Figure 5(a)). These differentially infiltrated immune cells were clustered into four groups (Figure 5(b)). The strongest correlation was found between T cells and CD8 T cells or Th17 cells in thymoma tissues (Figure 5(c)). In addition, we analyzed the correlation between key genes and immune cells (Figure 5(d)). LIPE had the strongest positive correlation with T cells and Th2 cells, MYH6 had the strongest positive correlation with NK cells, TF, KLF4, and aDC had the strongest positive correlation, SULT4A1 and pDC had the strongest positive correlation, and ACTG2 and neutrophils had the strongest positive correlation.

3.6. Regulatory Factors Associated with Thymoma

By comparing gene methylation modifications between thymoma and control, we obtained 943 differential methylation sites (Figure 6(a)). Among them, the methylation sites of chr1 accounted for the most, accounting for 13% (Figure 6(b)). Fourteen genes were identified as methylation factors because they had opposite levels of methylation and expression (Figure 6(c)). Among them, LIPE was significantly associated with OS in thymoma. In addition, GTF2I, the gene with the highest frequency of mutations in thymoma, was missense mutation in all samples (Figure 6(d)).

4. Discussion

Like other malignant tumors, the growth and proliferation of thymoma have many biological factors. However, the exact molecular basis of thymoma occurrence remains unclear. In this study, the possible molecular mechanism and regulatory factors of thymoma were explored through multiomics.

Early studies have shown that changes in certain genes seem to be associated with the development of thymic tumors [20, 21]. Our data suggest that there is a large difference in gene expression between thymoma and control. By identifying coexpression network constructed by genes with larger variance, module genes with high correlation with thymoma were obtained. Intersection with differentially expressed genes yielded 913 genes possibly associated with thymoma development.

GO functional enrichment analysis is very powerful and widely used to identify biological functions of gene expression data [22]. In the GO functional enrichment results, MAPK cascade, ERK1 and ERK2 cascade, response to transforming growth factor beta (TGF-β), and Wnt signaling pathway were mainly involved. Mitogen-activated protein kinase (MAPK) is a complex and interrelated signal cascade, which is closely related to the occurrence and progress of tumor, and plays an important regulatory role in cell proliferation, differentiation, migration, and survival [23, 24]. ERK 1/2 is also an effective target for anticancer [25]. Studies have shown that MAPK signal and ERK 1/2 were significantly activated in thymoma [26]. TGF-β inhibited apoptosis and had reduced expression of IFN-γ in effector cell, a key mediator of antitumor immunity [27]. Recently, it had been proved that Wnt pathway was activated in human thymoma, which may be involved in the tumorigenesis [28]. These findings further confirmed that a variety of inflammatory processes and cytokines were involved in the pathogenesis of thymoma.

In addition, in KEGG enrichment results, ECM also regulated intercellular communication, cell connectivity plasticity, and cell adhesion molecules interacting with various cytokines/chemokines or growth factors [29, 30]. There were 34% of the genes in the ECM-receptor interaction pathway mutated repeatedly in cancer [31]. Focal adhesion kinase (FAK) is highly expressed in thymic epithelial tumors and can be used as an independent prognostic biomarker [32]. PPARγ overexpression more than doubled insulin-stimulated thymoma viral protooncogene phosphorylation during low lipid availability [33]. GSEA results had the same terms as KEGG enrichment results, in which cholesterol accumulation was a common feature of cancer tissues. Recent evidence showed that cholesterol played a crucial role in the progress of cancer including breast, prostate, and colorectal cancer [34]. Activation of cGMP PKG signal may promote the growth of cervical cancer cells [35].

By screening the DEGs that had a significant impact on the prognosis of thymoma, we identified LIPE, MYH6, ACTG2, KLF4, SULT4A1, and TF as key genes. LIPE was also predicted as a new prognostic marker of thymoma in other studies [36]. Consistent with our analysis, MYH6 was differentially expressed in thymoma [37]. We found that MYH6 may be a potential target for thymoma. ACTG2, KLF4, SULT4A1, and TF were all involved in the occurrence or development of cancer, but their biological significance in thymoma was not clear [3841]. This needs further study and discussion of the follow-up experiments.

From the perspective of immune microenvironment, innate immune cells such as DC and adaptive immune cells such as T cells played an important role in thymoma [13, 42, 43]. There was a strong correlation between LIPE and immune cells, suggesting that LIPE may participate in the prognosis of thymoma by regulating the immunity system. Interestingly, we found that LIPE was also a gene regulated by methylation. DNA and RNA methylation genes are commonly studied as biomarkers [44, 45], which also seems to be a way for LIPE to participate in the development of thymoma [46]. On the other hand, genetic difference in thymoma was also an effective way to screen potential therapeutic targets [9]. GTF2I mutation occurs at high frequency in thymoma and is a marker of good prognosis [47].

However, this study also had some limitations. Firstly, conclusions may be limited by small samples, especially control samples. Secondly, the results of this study had not been verified by molecular experiments, so the interpretation of the results may be cautious. In this study, the possible molecular changes and pathogenesis of thymoma were investigated using the multiomics data from TCGA database. This study identified key genes related to the prognosis of thymoma, including LIPE, MYH6, ACTG2, KLF4, SULT4A1, and TF. The expression of these genes in thymoma may be a promising biomarker, which needs further study.

5. Conclusion

In this study, potential targets associated with thymoma were identified by combining thymoma-related gene expression, methylation, and mutation data. Using a variety of bioinformatics analysis methods, we found that important genes related to thymoma were associated with immune inflammatory response. LIPE, MYH6, ACTG2, KLF4, SULT4A1, and TF were the key genes affecting the prognosis of thymoma. Among them, LIPE was also modified by methylation.

Data Availability

Thymoma mRNA-seq expression data, methylation data, mutation data, and clinical materials were obtained from TCGA website (

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Dazhong Liu and Pengfei Zhang contributed equally to this article as co-first authors.


This study was supported by the Project of Heilongjiang Health and Family Planning Commission (2016-066) and Science and Technology Innovation Talent Project of Harbin Science and Technology Bureau (2016RAQXJ149).


  1. L. Yu, J. Ke, X. du, Z. Yu, and D. Gao, “Genetic characterization of thymoma,” Scientific Reports, vol. 9, no. 1, p. 2369, 2019. View at: Publisher Site | Google Scholar
  2. M. A. den Bakker, A. C. Roden, A. Marx, and M. Marino, “Histologic classification of thymoma: a practical guide for routine cases,” Journal of Thoracic Oncology, vol. 9, no. 9, pp. S125–S130, 2014. View at: Publisher Site | Google Scholar
  3. B. Aydemir, “The effect of myasthenia gravis as a prognostic factor in thymoma treatment,” Northern Clinics of Istanbul, vol. 3, no. 3, pp. 194–200, 2016. View at: Publisher Site | Google Scholar
  4. Y. Sun, C. Gu, J. Shi et al., “Reconstruction of mediastinal vessels for invasive thymoma: a retrospective analysis of 25 cases,” Journal of Thoracic Disease, vol. 9, no. 3, pp. 725–733, 2017. View at: Publisher Site | Google Scholar
  5. D. J. Kim, W. I. Yang, S. S. Choi, K. D. Kim, and K. Y. Chung, “Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review,” Chest, vol. 127, no. 3, pp. 755–761, 2005. View at: Publisher Site | Google Scholar
  6. D. Bian, F. Zhou, W. Yang et al., “Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study,” Oncotarget, vol. 9, no. 15, pp. 12273–12283, 2018. View at: Publisher Site | Google Scholar
  7. M. Radovich, C. R. Pickering, I. Felau et al., “The integrated genomic landscape of thymic epithelial tumors,” Cancer Cell, vol. 33, no. 2, pp. 244–258.e10, 2018, e10. View at: Publisher Site | Google Scholar
  8. T. Sakane, T. Murase, K. Okuda et al., “A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3,” Histopathology, vol. 75, no. 5, pp. 755–766, 2019. View at: Publisher Site | Google Scholar
  9. F. Enkner, B. Pichlhöfer, A. T. Zaharie et al., “Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets,” Pathology Oncology Research, vol. 23, no. 3, pp. 551–564, 2017. View at: Publisher Site | Google Scholar
  10. S. Li, Y. Yuan, H. Xiao et al., “Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors,” Clinical Epigenetics, vol. 11, no. 1, p. 38, 2019. View at: Publisher Site | Google Scholar
  11. M. Venza, M. Visalli, C. Beninati, C. Biondo, D. Teti, and I. Venza, “Role of genetics and epigenetics in mucosal, uveal, and cutaneous melanomagenesis,” Anti-Cancer Agents in Medicinal Chemistry, vol. 16, no. 5, pp. 528–538, 2016. View at: Publisher Site | Google Scholar
  12. P. Christopoulos and P. Fisch, “Acquired T-cell immunodeficiency in thymoma patients,” Critical Reviews in Immunology, vol. 36, no. 4, pp. 315–327, 2016. View at: Publisher Site | Google Scholar
  13. M. Omatsu, T. Kunimura, T. Mikogami et al., “Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors,” Diagnostic Pathology, vol. 9, no. 1, p. 215, 2014. View at: Publisher Site | Google Scholar
  14. C. Gu, X. Shi, Z. Huang et al., “A comprehensive study of construction and analysis of competitive endogenous RNA networks in lung adenocarcinoma,” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol. 1868, no. 8, p. 140444, 2020. View at: Publisher Site | Google Scholar
  15. X. Shi, T. Huang, J. Wang et al., “Next-generation sequencing identifies novel genes with rare variants in total anomalous pulmonary venous connection,” eBioMedicine, vol. 38, pp. 217–227, 2018. View at: Publisher Site | Google Scholar
  16. C. Gu, Z. Huang, X. Chen et al., “TEAD4 promotes tumor development in patients with lung adenocarcinoma via ERK signaling pathway,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1866, no. 12, article 165921, 2020. View at: Publisher Site | Google Scholar
  17. C. Gu, X. Shi, X. Dang et al., “Identification of common genes and pathways in eight fibrosis diseases,” Frontiers in Genetics, vol. 11, p. 627396, 2020. View at: Publisher Site | Google Scholar
  18. C. Gu, R. Wang, X. Pan et al., “Comprehensive study of prognostic risk factors of patients underwent pneumonectomy,” Journal of Cancer, vol. 8, no. 11, pp. 2097–2103, 2017. View at: Publisher Site | Google Scholar
  19. C. Gu, X. Pan, R. Wang et al., “Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component,” Oncotarget, vol. 7, no. 17, pp. 24596–24603, 2016. View at: Publisher Site | Google Scholar
  20. X. D. Wang, P. Lin, Y. X. Li et al., “Identification of potential agents for thymoma by integrated analyses of differentially expressed tumour-associated genes and molecular docking experiments,” Experimental and Therapeutic Medicine, vol. 18, no. 3, pp. 2001–2014, 2019. View at: Publisher Site | Google Scholar
  21. F. J. Meng, S. Wang, J. Zhang et al., “Alteration in gene expression profiles of thymoma: genetic differences and potential novel targets,” Thoracic Cancer, vol. 10, no. 5, pp. 1129–1135, 2019. View at: Publisher Site | Google Scholar
  22. K. Rue-Albrecht, P. A. McGettigan, B. Hernández et al., “GOexpress: an R/bioconductor package for the identification and visualisation of robust gene ontology signatures through supervised learning of gene expression data,” BMC Bioinformatics, vol. 17, no. 1, p. 126, 2016. View at: Publisher Site | Google Scholar
  23. C. Braicu, M. Buse, C. Busuioc et al., “A comprehensive review on MAPK: a promising therapeutic target in cancer,” Cancers, vol. 11, no. 10, p. 1618, 2019. View at: Publisher Site | Google Scholar
  24. M. Cargnello and P. P. Roux, “Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases,” Microbiology and Molecular Biology Reviews, vol. 75, no. 1, pp. 50–83, 2011. View at: Publisher Site | Google Scholar
  25. A. Plotnikov, K. Flores, G. Maik-Rachline et al., “The nuclear translocation of ERK1/2 as an anticancer target,” Nature Communications, vol. 6, no. 1, p. 6685, 2015. View at: Publisher Site | Google Scholar
  26. Z. Yang, S. Liu, Y. Wang et al., “High expression of KITLG is a new hallmark activating the MAPK pathway in type A and AB thymoma,” Thoracic Cancer, vol. 11, no. 7, pp. 1944–1954, 2020. View at: Publisher Site | Google Scholar
  27. M. Ibrahim, D. Scozzi, K. A. Toth et al., “Naive CD4+T cells carrying a TLR2 agonist overcome TGF-β–mediated tumor immune evasion,” Journal of Immunology, vol. 200, no. 2, pp. 847–856, 2018. View at: Publisher Site | Google Scholar
  28. P. Vodicka, L. Krskova, I. Odintsov et al., “Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas,” Oncology Letters, vol. 19, no. 3, pp. 2413–2421, 2020. View at: Publisher Site | Google Scholar
  29. H. E. Barker, J. T. E. Paget, A. A. Khan, and K. J. Harrington, “The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence,” Nature Reviews. Cancer, vol. 15, no. 7, pp. 409–425, 2015. View at: Publisher Site | Google Scholar
  30. C. Ionescu, C. Braicu, R. Chiorean et al., “TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: a pilot study,” Journal of Gastrointestinal and Liver Diseases, vol. 23, no. 4, pp. 413–418, 2020. View at: Publisher Site | Google Scholar
  31. B. Liu, F. F. Hu, Q. Zhang et al., “Genomic landscape and mutational impacts of recurrently mutated genes in cancers,” Molecular Genetics & Genomic Medicine, vol. 6, no. 6, pp. 910–923, 2018. View at: Publisher Site | Google Scholar
  32. M. Li, F. Hou, J. Zhao et al., “Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker,” Oncology Letters, vol. 15, no. 3, pp. 3001–3007, 2018. View at: Publisher Site | Google Scholar
  33. S. Hu, J. Yao, A. A. Howe et al., “Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle,” Molecular Endocrinology, vol. 26, no. 6, pp. 977–988, 2012. View at: Publisher Site | Google Scholar
  34. T. Murai, “Cholesterol lowering: role in cancer prevention and treatment,” Biological Chemistry, vol. 396, no. 1, pp. 1–11, 2015. View at: Publisher Site | Google Scholar
  35. L. Gong, Y. Lei, X. Tan et al., “Propranolol selectively inhibits cervical cancer cell growth by suppressing the cGMP/PKG pathway,” Biomedicine & Pharmacotherapy, vol. 111, pp. 1243–1248, 2019. View at: Publisher Site | Google Scholar
  36. Q. Li, Y. L. Su, and W. X. Shen, “A novel prognostic signature of seven genes for the prediction in patients with thymoma,” Journal of Cancer Research and Clinical Oncology, vol. 145, no. 1, pp. 109–116, 2019. View at: Publisher Site | Google Scholar
  37. J. Xi, L. Wang, C. Yan et al., “The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells,” Journal of Thoracic Disease, vol. 11, no. 6, pp. 2315–2323, 2019. View at: Publisher Site | Google Scholar
  38. A. Simiczyjew, A. J. Mazur, E. Dratkiewicz, and D. Nowak, “Involvement of β- and γ-actin isoforms in actin cytoskeleton organization and migration abilities of bleb-forming human colon cancer cells,” PLoS One, vol. 12, no. 3, article e0173709, 2017. View at: Publisher Site | Google Scholar
  39. M. Moral, C. Segrelles, A. B. Martínez-Cruz et al., “Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma,” In Vivo, vol. 23, no. 5, pp. 653–660, 2009. View at: Google Scholar
  40. J. Dai, Z. Bing, Y. Zhang et al., “Integrated mRNAseq and microRNAseq data analysis for grade III gliomas,” Molecular Medicine Reports, vol. 16, no. 5, pp. 7468–7478, 2017. View at: Publisher Site | Google Scholar
  41. D. Ferreira, R. Ponraj, A. Yeung, and J. de Malmanche, “Pure red cell aplasia associated with thymolipoma: complete anaemia resolution following thymectomy,” Case Reports in Hematology, vol. 2018, Article ID 8627145, 4 pages, 2018. View at: Publisher Site | Google Scholar
  42. L. Wang, O. E. Branson, K. Shilo, C. L. Hitchcock, and M. A. Freitas, “Proteomic signatures of thymomas,” PLoS One, vol. 11, no. 11, article e0166494, 2016. View at: Publisher Site | Google Scholar
  43. S. Shelly, N. Agmon-Levin, A. Altman, and Y. Shoenfeld, “Thymoma and autoimmunity,” Cellular & Molecular Immunology, vol. 8, no. 3, pp. 199–202, 2011. View at: Publisher Site | Google Scholar
  44. C. Gu, X. Shi, C. Dai et al., “RNA m6A modification in cancers: molecular mechanisms and potential clinical applications,” The Innovation, vol. 1, no. 3, p. 100066, 2020. View at: Publisher Site | Google Scholar
  45. C. Gu and C. Chen, “Methylation in lung cancer: a brief review,” Methods in Molecular Biology, vol. 2204, pp. 91–97, 2020. View at: Publisher Site | Google Scholar
  46. Y. Bi, Y. Meng, Y. Niu et al., “Genome‑wide DNA methylation profile of thymomas and potential epigenetic regulation of thymoma subtypes,” Oncology Reports, vol. 41, no. 5, pp. 2762–2774, 2019. View at: Publisher Site | Google Scholar
  47. I. Petrini, P. S. Meltzer, I. K. Kim et al., “A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors,” Nature Genetics, vol. 46, no. 8, pp. 844–849, 2014. View at: Publisher Site | Google Scholar

Copyright © 2021 Dazhong Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.